-
Innovation Ranking
NewInnovation Ranking – XOMA Corp
XOMA Corp (Xoma), formerly Xoma Ltd, is a biopharmaceutical company. It develops antibody-based therapeutics. Its lead product, Gevokizumab is a monoclonal antibody used for the treatment of a wide variety of inflammatory diseases and other diseases. Its other pipeline products include RZ358, TAK-079, AZD2936 and PTH1R. XOMA X358 is a human negative allosteric modulating insulin receptor antibody. Xoma has a developed proprietary antibody platform, optimization and development technologies, comprising ADAPT, ModulX and OptimX. It operates through its subsidiaries in Bermuda,...
-
Product Insights
Hyperparathyroidism – Drugs In Development, 2023
Global Markets Direct’s, ‘Hyperparathyroidism - Drugs In Development, 2023’, provides an overview of the Hyperparathyroidism pipeline landscape. The report provides comprehensive information on the therapeutics under development for Hyperparathyroidism, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Humoral Hypercalcemia of Malignancy – Drugs In Development, 2023
Global Markets Direct’s, ‘Humoral Hypercalcemia of Malignancy - Drugs In Development, 2023’, provides an overview of the Humoral Hypercalcemia of Malignancy pipeline landscape. The report provides comprehensive information on the therapeutics under development for Humoral Hypercalcemia of Malignancy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
NewNet Present Value Model: XOMA Corp’s RZ-358
Empower your strategies with our Net Present Value Model: XOMA Corp's RZ-358 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: XOMA Corp’s Iscalimab
Empower your strategies with our Net Present Value Model: XOMA Corp's Iscalimab report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
Uveitis Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
Uveitis Clinical Trials Market Report Overview The uveitis clinical trial market research report provides an overview of the uveitis clinical trials scenario. The report provides top-line data relating to the clinical trials on uveitis. It also includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. Moreover, it offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status, and sponsor type. Key Regions North America,...
-
Company Profile
XOMA Corp – Company Profile
XOMA Corp (Xoma), formerly Xoma Ltd, is a biopharmaceutical company. It develops antibody-based therapeutics. Its lead product, Gevokizumab is a monoclonal antibody used for the treatment of a wide variety of inflammatory diseases and other diseases. Its other pipeline products include RZ358, TAK-079, AZD2936 and PTH1R. XOMA X358 is a human negative allosteric modulating insulin receptor antibody. Xoma has a developed proprietary antibody platform, optimization and development technologies, comprising ADAPT, ModulX and OptimX. It operates through its subsidiaries in Bermuda,...
Add to Basket -
Product Insights
Colon Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Colon Cancer Pipeline Drugs Market Overview Colon cancer is cancer that starts in the large intestine (colon). There is no single cause of colon cancer. Nearly all colon cancers begin as noncancerous (benign) polyps, which slowly develop into cancer. Many cases of colon cancer have no symptoms. The following symptoms may indicate colon cancer abdominal pain and tenderness in the lower abdomen, blood in the stool, diarrhea, constipation, or other change in bowel habits, narrow stools, and weight loss with...